This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Betticher, D. C. Articles by Ris, H.-B. Search for Related Content PubMed PubMed Citation Articles by Betticher, D. C. Articles by Ris, H.-B. Social Bookmarking                            What's this?

Mediastinal Lymph Node Clearance After Docetaxel-Cisplatin Neoadjuvant Chemotherapy Is Prognostic of Survival in Patients With Stage IIIA pN2 Non–Small-Cell Lung Cancer: A Multicenter Phase II Trial

Daniel C. Betticher, Shu-Fang Hsu Schmitz, Martin Tötsch, Eva Hansen, Christine Joss, Christian von Briel, Ralph A. Schmid, Miklos Pless, James Habicht, Arnaud D. Roth, Anastase Spiliopoulos, Rolf Stahel, Walter Weder, Roger Stupp, Fritz Egli, Markus Furrer, Hanspeter Honegger, Martin Wernli, Thomas Cerny, Hans-Beat Ris

From the Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland.

Address reprint requests to Daniel Betticher, MD, Institute of Medical Oncology, University of Bern, 3010 Bern, Switzerland; email: daniel.betticher{at}insel.ch.

Purpose: A multicenter, phase II trial investigated the efficacy and toxicity of neoadjuvant docetaxel-cisplatin in locally advanced non–small-cell lung cancer (NSCLC) and examined prognostic factors for patients not benefiting from surgery.

Patients and Methods: Ninety patients with previously untreated, potentially operable stage IIIA (mediastinoscopically pN2) NSCLC received three cycles of docetaxel 85 mg/m² day 1 plus cisplatin 40 mg/m² days 1 and 2, with subsequent surgical resection.

Results: Administered dose-intensities were docetaxel 85 mg/m²/3 weeks (range, 53 to 96) and cisplatin 95 mg/m²/3 weeks (range, 0 to 104). The 265 cycles were well tolerated, and the overall response rate was 66% (95% confidence interval [CI], 55% to 75%). Seventy-five patients underwent tumor resection with positive resection margin and involvement of the uppermost mediastinal lymph node in 16% and 35% of patients, respectively (perioperative mortality, 3%; morbidity, 17%). Pathologic complete response occurred in 19% of patients with tumor resection. In patients with tumor resection, downstaging to N0–1 at surgery was prognostic and significantly prolonged event-free survival (EFS) and overall survival (OS; P = .0001). At median follow-up of 32 months, the median EFS and OS were 14.8 months (range, 2.4 to 53.4) and 33 months (range, 2.4 to 53.4), respectively. Local relapse occurred in 27% of patients with tumor resection, with distant metastases in 37%. Multivariate analyses identified mediastinal clearance (hazard ratio, 0.22; P = .0003) and complete resection (hazard ratio, 0.26; P = .0006) as strongly prognostic for increased survival.

Conclusion: Neoadjuvant docetaxel-cisplatin is effective and tolerable in stage IIIA pN2 NSCLC. Resection is recommended only for patients with mediastinal downstaging after chemotherapy.

Supported by an unrestricted grant used for part of the trial data management from Aventis Pharmaceuticals, Zurich, Switzerland.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				V. Steger, T. Walles, B. Kosan, T. Walker, T. Kyriss, S. Veit, J. Dippon, and G. Friedel Trimodal Therapy for Histologically Proven N2/3 Non-Small Cell Lung Cancer: Mid-Term Results and Indicators for Survival. Ann. Thorac. Surg., June 1, 2009; 87(6): 1676 - 1683. [Abstract] [Full Text] [PDF]

				F. J.F. Herth, J. T. Annema, R. Eberhardt, K. Yasufuku, A. Ernst, M. Krasnik, and R. C. Rintoul Endobronchial Ultrasound With Transbronchial Needle Aspiration for Restaging the Mediastinum in Lung Cancer J. Clin. Oncol., July 10, 2008; 26(20): 3346 - 3350. [Abstract] [Full Text] [PDF]

				Z. Mansour, E. A. Kochetkova, N. Santelmo, X. Ducrocq, E. Quoix, J.-M. Wihlm, and G. Massard Persistent N2 Disease After Induction Therapy Does Not Jeopardize Early and Medium Term Outcomes of Pneumonectomy Ann. Thorac. Surg., July 1, 2008; 86(1): 228 - 233. [Abstract] [Full Text] [PDF]

				P.-E. Falcoz Invited Commentary Ann. Thorac. Surg., July 1, 2008; 86(1): 233 - 234. [Full Text] [PDF]

				W. Zhong, X. Yang, J. Bai, J. Yang, C. Manegold, and Y. Wu Complete mediastinal lymphadenectomy: the core component of the multidisciplinary therapy in resectable non-small cell lung cancer. Eur. J. Cardiothorac. Surg., July 1, 2008; 34(1): 187 - 195. [Abstract] [Full Text] [PDF]

				M. De Waele, M. Serra-Mitjans, J. Hendriks, P. Lauwers, J. Belda-Sanchis, P. Van Schil, and R. Rami-Porta Accuracy and survival of repeat mediastinoscopy after induction therapy for non-small cell lung cancer in a combined series of 104 patients Eur. J. Cardiothorac. Surg., May 1, 2008; 33(5): 824 - 828. [Abstract] [Full Text] [PDF]

				N. Pourel, N. Santelmo, N. Naafa, A. Serre, W. Hilgers, L. Mineur, N. Molinari, and F. Reboul Concurrent cisplatin/etoposide plus 3D-conformal radiotherapy followed by surgery for stage IIB (superior sulcus T3N0)/III non-small cell lung cancer yields a high rate of pathological complete response Eur. J. Cardiothorac. Surg., May 1, 2008; 33(5): 829 - 836. [Abstract] [Full Text] [PDF]

				P. E. Van Schil and M. De Waele A second mediastinoscopy: how to decide and how to do it? Eur. J. Cardiothorac. Surg., April 1, 2008; 33(4): 703 - 706. [Abstract] [Full Text] [PDF]

				A. Marra, L. Hillejan, S. Fechner, and G. Stamatis Remediastinoscopy in restaging of lung cancer after induction therapy. J. Thorac. Cardiovasc. Surg., April 1, 2008; 135(4): 843 - 849. [Abstract] [Full Text] [PDF]

				P. Garrido, J. L. Gonzalez-Larriba, A. Insa, M. Provencio, A. Torres, D. Isla, J. M. Sanchez, F. Cardenal, M. Domine, J. R. Barcelo, et al. Long-Term Survival Associated With Complete Resection After Induction Chemotherapy in Stage IIIA (N2) and IIIB (T4N0-1) Non Small-Cell Lung Cancer Patients: The Spanish Lung Cancer Group Trial 9901 J. Clin. Oncol., October 20, 2007; 25(30): 4736 - 4742. [Abstract] [Full Text] [PDF]

				P. De Leyn, D. Lardinois, P. E. Van Schil, R. Rami-Porta, B. Passlick, M. Zielinski, D. A. Waller, T. Lerut, and W. Weder ESTS guidelines for preoperative lymph node staging for non-small cell lung cancer Eur. J. Cardiothorac. Surg., July 1, 2007; 32(1): 1 - 8. [Abstract] [Full Text] [PDF]

				J. P. van Meerbeeck, G. W. P. M. Kramer, P. E. Y. Van Schil, C. Legrand, E. F. Smit, F. Schramel, V. C. Tjan-Heijnen, B. Biesma, C. Debruyne, N. van Zandwijk, et al. Randomized Controlled Trial of Resection Versus Radiotherapy After Induction Chemotherapy in Stage IIIA-N2 Non-Small-Cell Lung Cancer J Natl Cancer Inst, March 21, 2007; 99(6): 442 - 450. [Abstract] [Full Text] [PDF]

				P. Macchiarini, M. Altmayer, T. Go, T. Walles, K. Schulze, I. Wildfang, A. Haverich, M. Hardin, and Hannover Interdisciplinary Intrathoracic Tumor Tas Technical Innovations of Carinal Resection for Nonsmall-Cell Lung Cancer Ann. Thorac. Surg., December 1, 2006; 82(6): 1989 - 1997. [Abstract] [Full Text] [PDF]

				P. De Leyn, S. Stroobants, W. De Wever, T. Lerut, W. Coosemans, G. Decker, P. Nafteux, D. Van Raemdonck, L. Mortelmans, K. Nackaerts, et al. Prospective Comparative Study of Integrated Positron Emission Tomography-Computed Tomography Scan Compared With Remediastinoscopy in the Assessment of Residual Mediastinal Lymph Node Disease After Induction Chemotherapy for Mediastinoscopy-Proven Stage IIIA-N2 Non-Small-Cell Lung Cancer: A Leuven Lung Cancer Group Study J. Clin. Oncol., July 20, 2006; 24(21): 3333 - 3339. [Abstract] [Full Text] [PDF]

				E. D. Bernstein, S. M. Herbert, and N. H. Hanna Chemotherapy and Radiotherapy in the Treatment of Resectable Non-Small-Cell Lung Cancer Ann. Surg. Oncol., March 1, 2006; 13(3): 291 - 301. [Abstract] [Full Text] [PDF]

				M. De Waele, J. Hendriks, P. Lauwers, P. Ortmanns, W. Vanroelen, A.-M. Morel, P. Germonpre, and P. Van Schil Nodal status at repeat mediastinoscopy determines survival in non-small cell lung cancer with mediastinal nodal involvement, treated by induction therapy Eur. J. Cardiothorac. Surg., February 1, 2006; 29(2): 240 - 243. [Abstract] [Full Text] [PDF]

				D. Galetta, A. Cesario, S. Margaritora, V. Porziella, A. Piraino, R. M. D'Angelillo, M. A. Gambacorta, S. Ramella, L. Trodella, S. Valente, et al. Multimodality treatment of unresectable stage III non-small cell lung cancer: Interim analysis of a phase II trial with preoperative gemcitabine and concurrent radiotherapy J. Thorac. Cardiovasc. Surg., February 1, 2006; 131(2): 314 - 321. [Abstract] [Full Text] [PDF]

				M. de Perrot, E. Fadel, O. Mercier, S. Mussot, A. Chapelier, and P. Dartevelle Long-term results after carinal resection for carcinoma: Does the benefit warrant the risk? J. Thorac. Cardiovasc. Surg., January 1, 2006; 131(1): 81 - 89. [Abstract] [Full Text] [PDF]

				N. Ramnath, E. Sommers, L. Robinson, C. Nwogu, A. Sharma, A. Cantor, and G. Bepler Phase II Study of Neoadjuvant Chemotherapy With Gemcitabine and Vinorelbine in Resectable Non-small Cell Lung Cancer Chest, November 1, 2005; 128(5): 3467 - 3474. [Abstract] [Full Text] [PDF]

				F. Barlesi, C. Doddoli, J.-P. Torre, R. Giudicelli, P. Fuentes, P. Thomas, and P. Astoul Comparative prognostic features of stage IIIAN2 and IIIB non-small-cell lung cancer patients treated with surgery after induction therapy Eur. J. Cardiothorac. Surg., October 1, 2005; 28(4): 629 - 634. [Abstract] [Full Text] [PDF]

				B. Milleron, V. Westeel, E. Quoix, D. Moro-Sibilot, D. Braun, B. Lebeau, A. Depierre, and for the French Thoracic Cooperative Group Complete Response Following Preoperative Chemotherapy for Resectable Non-Small Cell Lung Cancer: Accuracy of Clinical Assessment Using the French Trial Database Chest, September 1, 2005; 128(3): 1442 - 1447. [Abstract] [Full Text] [PDF]

				C. Doddoli, F. Barlesi, D. Trousse, S. Robitail, S. Yena, P. Astoul, R. Giudicelli, P. Fuentes, and P. Thomas One hundred consecutive pneumonectomies after induction therapy for non-small cell lung cancer: An uncertain balance between risks and benefits J. Thorac. Cardiovasc. Surg., August 1, 2005; 130(2): 416 - 425. [Abstract] [Full Text] [PDF]

				A. T. Turrisi III Creeping Phase II-ism and the Medical Pharmaceutical Complex: Weapons of Mass Distraction in the War Against Lung Cancer J. Clin. Oncol., August 1, 2005; 23(22): 4827 - 4829. [Full Text] [PDF]

				E. Pezzetta, R. Stupp, A. Zouhair, L. Guillou, P. Taffe, C. von Briel, T. Krueger, and H.-B. Ris Comparison of neoadjuvant cisplatin-based chemotherapy versus radiochemotherapy followed by resection for stage III (N2) NSCLC Eur. J. Cardiothorac. Surg., June 1, 2005; 27(6): 1092 - 1098. [Abstract] [Full Text] [PDF]

				D. Farray, N. Mirkovic, and K. S. Albain Multimodality Therapy for Stage III Non-Small-Cell Lung Cancer J. Clin. Oncol., May 10, 2005; 23(14): 3257 - 3269. [Abstract] [Full Text] [PDF]

				J. K. LeBlanc, B. M. Devereaux, T. F. Imperiale, K. Kesler, J. M. DeWitt, O. Cummings, D. Ciaccia, S. Sherman, P. Mathur, D. Conces, et al. Endoscopic Ultrasound in Non-Small Cell Lung Cancer and Negative Mediastinum on Computed Tomography Am. J. Respir. Crit. Care Med., January 15, 2005; 171(2): 177 - 182. [Abstract] [Full Text] [PDF]

				I. S. Choi, D.-Y. Oh, J. H. Kwon, S.-I. Kim, S. R. Park, J.-Y. Bak, J. H. Kim, D.-W. Kim, Y. T. Kim, T.-Y. Kim, et al. Paclitaxel/Platinum-based Perioperative Chemotherapy and Surgery in Stage IIIA Non-small Cell Lung Cancer Jpn. J. Clin. Oncol., January 1, 2005; 35(1): 6 - 12. [Abstract] [Full Text] [PDF]

				N. Lorent, P. De Leyn, Y. Lievens, E. Verbeken, K. Nackaerts, C. Dooms, D. Van Raemdonck, B. Anrys, J. Vansteenkiste, and The Leuven Lung Cancer Group Long-term survival of surgically staged IIIA-N2 non-small-cell lung cancer treated with surgical combined modality approach: analysis of a 7-year prospective experience Ann. Onc., November 1, 2004; 15(11): 1645 - 1653. [Abstract] [Full Text] [PDF]

				W. Weder, P. Kestenholz, C. Taverna, S. Bodis, D. Lardinois, M. Jerman, and R. A. Stahel Neoadjuvant Chemotherapy Followed by Extrapleural Pneumonectomy in Malignant Pleural Mesothelioma J. Clin. Oncol., September 1, 2004; 22(17): 3451 - 3457. [Abstract] [Full Text] [PDF]

				R. Rosell, E. Felip, M. Taron, J. Majo, P. Mendez, M. Sanchez-Ronco, C. Queralt, J. J. Sanchez, and J. Maestre Gene Expression as a Predictive Marker of Outcome in Stage IIB-IIIA-IIIB Non-Small Cell Lung Cancer After Induction Gemcitabine-Based Chemotherapy Followed By Resectional Surgery Clin. Cancer Res., June 15, 2004; 10(12): 4215S - 4219S. [Abstract] [Full Text] [PDF]

				B. C. Jacobson, M. K. Gould, G. A. Silvestri, F. Detterbeck, A. Papagiannis, A. Buyukcelik, B. Yalcin, G. Utkan, A. Spira, and D. S. Ettinger Multidisciplinary Management of Lung Cancer N. Engl. J. Med., May 6, 2004; 350(19): 2008 - 2010. [Full Text] [PDF]

				L. Trodella, P. Granone, S. Valente, S. Margaritora, G. Macis, A. Cesario, R. M. D'Angelillo, V. Valentini, G. M. Corbo, V. Porziella, et al. Neoadjuvant concurrent radiochemotherapy in locally advanced (IIIA-IIIB) non-small-cell lung cancer: long-term results according to downstaging Ann. Onc., March 1, 2004; 15(3): 389 - 398. [Abstract] [Full Text] [PDF]